CRSP - Crispr Therapeutics: Investors Bet Against Casgevy Uptake

2024-02-01 13:20:32 ET

Summary

• Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia.
• In this article I'll look at Casgevy's market potential and its commercialisation challenges.
• The cost of Casgevy, treatment cons, scalability and accessibility pose serious challenges for widespread adoption. Which may justify the high short interest in the stock.

Crispr Therapeutics ( CRSP ) recently received approval for their gene editing therapy, CASGEVY used for treating inherited illnesses Sickle Cell Disease and Beta-Thalassemia....

For further details see: